CELL INTELLIGENCE · 肿瘤细胞治疗研究

CAR-T 细胞治疗后的感染并发症：机制、风险分层与预防

Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention.

基于 FAERS 数据的靶向 B 细胞成熟抗原免疫治疗中细胞因子释放综合征的信号检测与机器学习预测

Signal Detection and Machine Learning-Based Prediction of Cytokine Release Syndrome in B-Cell Maturation Antigen-Targeting Immunotherapies Using FAERS

多发性骨髓瘤中 BCMA 的生物学与治疗靶向：从配体信号到抗原逃逸

BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape.

靶向复发/难治性多发性骨髓瘤中的 B 细胞成熟抗原：即将迎来其黄金时期

Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: On the verge of its prime time.

CAR-T 细胞疗法在实体瘤中的挑战与局限：为何获批仅限于血液系统恶性肿瘤？

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

基于 CAR 的细胞与基因治疗：来自 ClinicalTrials.gov 的全球临床格局与新兴治疗策略

CAR-Based Cell and Gene Therapies: Global Clinical Landscape and Emerging Therapeutic Strategies from ClinicalTrials.gov.

肿瘤预激 CD8⁺ 自然杀伤 T 样细胞作为复发/难治性多发性骨髓瘤的高效新型细胞疗法

Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.

TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。

接受 CAR-T 细胞治疗的血液系统恶性肿瘤患者中免疫效应细胞相关神经毒性的发生率：系统综述与荟萃分析

Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic rev

CAR-T 细胞疗法相关 ICANS 的总体发生率为全级别 26.9%、高级别 10.5%。

靶向 BCMA 的 CAR NK92 细胞在体外和体内均能有效杀伤多发性骨髓瘤细胞

CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo.